BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by ...

We recently published a list of 10 Best Falling Stocks To Buy According to Hedge Funds. In this article, we are going to take ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report)’s stock price reached a new 52-week low during trading on Wednesday following a weaker than expected earnings announcement. The stock ...

Blue Trust Inc. raised its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 504.9% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 859 shares ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) saw a large increase in short interest during the month of October. As of October 15th, there was short interest totalling 5,590,000 shares ...

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) had its price target dropped by equities research analysts at Citigroup from $93.00 to $81.00 in a research report issued on Wednesday, Benzinga ...

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at three upcoming investor conferences.

Sequoia Financial Advisors LLC purchased a new stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) during the third quarter, according to the company in its most recent 13F ...

BioMarin posts Q3 EPS of $0.91, nearly doubling last year's $0.46 and topping estimates. Sales rose 28%, driven by strong ...

Biomarin Pharmaceutical Inc (BMRN) reports a 28% revenue increase and raises full-year guidance amid strong performance and strategic initiatives.

A total of 27 analyst ratings have been received for Biomarin Pharmaceutical, with the consensus rating being Outperform. The average one-year price target stands at $100.85, suggesting a potential 44 ...

In a report released today, George Farmer from Scotiabank maintained a Hold rating on BioMarin Pharmaceutical (BMRN – Research Report), ...